Neuron Guard
Neuron Guard is developing a medical device the new standard of care for targeted temperature management of brain damages.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 374.9x EV/Revenue -18.7x EV/EBITDA | round | |
€650k | Convertible | ||
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (88 %) | (82 %) | 352 % | - | - | (75 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 2 % | (842 %) | (6020 %) | (2000 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (49 %) | (1110 %) | (6614 %) | (2109 %) | - | (27 %) | (309 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
NeuronGuard is a pioneering company focused on addressing the critical issue of Acute Brain Damage (ABD), which is a significant and growing challenge in modern medicine. The company offers an integrated solution that combines hypothermia and sedation to limit brain damage and improve patient outcomes. This solution is particularly vital given that ABD is the second leading cause of death for individuals over 50 and a leading cause of long-term disability, with substantial associated healthcare costs.
NeuronGuard primarily serves hospitals, emergency medical services, and intensive care units that deal with patients suffering from acute brain injuries such as strokes and traumatic brain injuries. The company operates in the medical technology market, targeting regions with high incidences of ABD, including the US and the EU.
The business model revolves around the sale and distribution of its integrated cerebral protection system to healthcare providers. Revenue is generated through direct sales, partnerships with medical institutions, and potentially through licensing agreements for its technology.
NeuronGuard's innovative approach and proven efficacy have earned it recognition, including winning the Seedcorn Funding Competition 2018 by NIHR Brain Injury MIC and the 7th Springboard Intesa Sanpaolo London Hub.
Keywords: Acute Brain Damage, Hypothermia, Sedation, Stroke, Traumatic Brain Injury, Medical Technology, Healthcare, Emergency Services, Patient Outcomes, Brain Protection.